A preliminary report of the efficacy of Debrisan (dextranomer) in the debridement of cutaneous ulcers.

A randomized trial involving 50 patients has demonstrated that a new type of debriding agent, cross-linked dextran beads with the trade name Debrisan (dextranomer, Pharmacia, Inc.), will produce rapid healing of cutaneous ulcers which have been resistant to conventional therapy over the long-term. Evaluation in terms of a number of therapeutic parameters, including rate of healing, dehydration, sterilization, loss of symptoms, and improvement in physiology, is included in this preliminary study.

RCT Entities:   Population Interventions Outcomes